{'fraction_non_alphanumeric': 0.022970903522205207, 'fraction_numerical': 0.0, 'mean_word_length': 4.891891891891892, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Biochemical markers of bone turnover. New aspect. Bone metabolic markers in prostatic carcinoma].

Hormonal therapy against prostatic carcinoma brings to osteoporotic change and alendronate is effective to suppress the change. Urinary NTX and serum ICTP are shown to be useful markers to react with hormonal therapy. But most of bone metabolic markers are not within normal range at the time of starting hormonal therapy. The program, which evaluate the effect of hormonal therapy against non-metastatic prostatic carcinoma, is strongly expected. And it is still a serious problem to be solved when we start, how to use, how long we use biphosphonates.